Mydecine to Report Full Year 2020 Financial Results on May 3, 2021
April 26, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, April 26, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
April 13, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, April 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
April 07, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, April 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND
April 07, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, April 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Announces Migration to NEO Exchange
March 23, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 23, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company...
Mydecine Innovations Group Provides Update on European Operations
March 16, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets
March 10, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
*NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DENVER, March 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF)...
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
March 01, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma company in the life sciences category...
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta
February 24, 2021 07:00 ET
|
Mydecine Innovations Group Inc.
Partnership Supports Mydecine’s Drug Development & Clinical Trials Pipeline Provides Update on Debt Settlement *NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN...
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology
February 17, 2021 07:00 ET
|
Mydecine Innovations Group Inc.
DENVER, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health...